Filing review petition will harm Hindu-Muslim unity, claims Rizvi

News Network
November 24, 2019

New Delhi, Nov 24: Filing a review petition challenging the Supreme Court's Ayodhya verdict will not be in the interest of Muslims and will "harm" Hindu-Muslim unity, National Commission for Minorities chairperson Ghayorul Hasan Rizvi said on Sunday.

The minority panel chief said filing the review petition would send a message to the Hindus that they were trying to put roadblocks in the way of building the Ram temple.

He also urged the Muslim side to accept the five-acre alternative land to be given for a mosque, saying they would be respecting the judiciary by doing so.

In an interview to PTI, Rizvi said the NCM had held a meeting after the Supreme Court verdict and all its members in one voice had said the verdict should be accepted.

The NCM chairperson said Muslims should help in building the temple in Ayodhya, while Hindus should help in the construction of the mosque. He said it would prove to be a milestone in strengthening the social harmony between the two communities.

According to Rizvi, filing of the review petition would send a message to the Hindus that the Muslim community wanted to put roadblocks in the way of building of the Ram temple in Ayodhya, which he said would "harm" Hindu-Muslim unity.

"Review petition should not be filed at all because all sides, including the All India Muslim Personal Law Board (AIMPLB) and the Jamiat Ulema-i-Hind, had promised that the verdict given by the Supreme Court will be respected," Rizvi said.

He alleged that Muslim bodies like the AIMPLB and the Jamiat were going back on their word after making the proclamation that the apex court's verdict would be respected.

"Not just now, for years they have been saying that they will accept the verdict by the Supreme Court, then what is the need for review?" Rizvi asked.

He wondered what was the point of the Muslim bodies in filing a review petition if they were also saying the review petition would be rejected "100 per cent".

"The common Muslim of this country is not in favour of a review petition because he or she does not want that matters which have been settled are again raised and the community gets caught up in such things," the NCM chief said.

"So the question is for whom are you filing the petition for? Are you filing the petition to harm the brotherhood and disturb the harmony among the communities? Are you doing this for your personal satisfaction?" he asked.

Rizvi said just four-five members of the AIMPLB, including All India Majlis-e-Ittehad-ul-Muslimeen (AIMIM) chief Asaduddin Owaisi, were in favour of filing a review petition.

The NCM chief alleged that Owaisi does politics using Muslims and wants to "keep them caught up in such issues so that he gets the votes".

Rizvi underscored that leaders should avoid all this as there are several issues of Muslims and work should be done for that.

"This (review) will not be in the interest of Muslims. As the chairman of the commission, a number of Muslims meet me everyday and they say that review should not be filed," he said.

"It will not be in the interest of Muslims because the message will go to the Hindus that Muslims want to keep the temple issue unresolved which in a way will harm Hindu-Muslim unity," Rizvi said.

In its judgement in the Babri Masjid-Ram Janmabhoomi title case on November 9, the Supreme Court had ruled that the entire 2.77 acres of disputed land should be handed over to deity 'Ram Lalla' (infant Ram), who was one of the three litigants.

The five-judge constitution bench also directed the Centre to allot a five-acre plot to the Sunni Waqf Board in Ayodhya to build a mosque.

Rizvi said the Muslim side should accept the five-acre land, adding that they would be respecting the government and the court by doing so.

"There are six-seven mosques in Ayodhya and Muslim population is not much so they suffice," he said. "But it is not an issue of mosque, if the Muslim side accepts the land to be allotted by the government, it will be respecting the government and the court."

The AIMPLB and the Maulana Arshad Madani-led Jamiat had announced last Sunday that a review petition would be filed against the Ayodhya verdict.

The board, after a meeting in Lucknow, had also said it was against accepting the five-acre alternative land given for a mosque as it "will neither balance equity nor repair the damage caused".

The Maulana Mahmood Madani-led faction of the Jamiat, however, has said filing a review would not be fruitful.

The Uttar Pradesh Sunni Central Waqf Board has said it would not file a review petition in the Ayodhya verdict. The board will hold a meeting to discuss various issues related to the verdict at its meeting on Tuesday.

Comments

abbu
 - 
Monday, 25 Nov 2019

rizvi jiii where is unity now within muslims and hindu.... raise your voice on lynching ... and other cases which is happening everyday to the muslims.... where is brotherhood now... even majority of hindus are saying that this verdict is not correct.. what u say abt that....

patroit
 - 
Sunday, 24 Nov 2019

robber come and attack your house and demolish then you go to supreme court of india to get justic but the court say give the land to robber who demolished your house....wah re waaa what a justic of our hindu suprem court...in other word

 

if you say we have power now & we are majoriry then mark my word in commining centure we will build the masjid in same place...

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
July 16,2020

New Delhi, Jul 16: With the highest single-day spike of 32,695 cases and 606 deaths reported in the last 24 hours, India's COVID-19 tally on Thursday reached 9,68,876, informed the Union Ministry of Health and Family Welfare on Thursday.

The total number of COVID-19 cases includes 3,31,146 active cases, 6,12,815 cured/discharged/migrated and 24,915 deaths.

As per the Ministry, Maharashtra -- the worst-affected state from the infection -- has a total of 2,75,640 COVID-19 cases and 10,928 fatalities. While Tamil Nadu has a tally of 1,51,820 cases and 2,167 deaths due to COVID-19.

Delhi has reported a total of 1,16,993 cases and 3,487 deaths due to COVID-19.

Meanwhile, as per the information provided by the Indian Council of Medical Research (ICMR), 1,27,39,490 samples have been tested for COVID-19 till 15th July, of these 3,26,826 samples were tested yesterday.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
January 21,2020

Jan 21: Indian policymakers may make it easier for companies to tap foreign funding, as a prolonged cash squeeze makes it tough for firms to borrow at home.

Investors are speculating about potential steps Finance Minister Nirmala Sitharaman could unveil when she presents the nation’s budget on Feb. 1. These measures may include freeing up firms to borrow at higher rates and offering tax breaks to global funds.

“The government will need to relax local rules to make it easier for Indian companies to raise debt overseas and tide over the funding crunch in the onshore market,” said Raj Kothari, London-based head of trading at Jay Capital Ltd. “At the same time, they need to ensure that the borrowers tapping offshore markets abide with stricter corporate governance so as to avoid further defaults.”

A prolonged crisis in India’s shadow bank sector and a pile of bad loans at traditional lenders is making it expensive for Indian companies, other than the best-rated firms, to access funding. The government has tried a series of measures to spur domestic credit, including providing so-called credit enhancement and allowing tiny firms to restructure debt.

Here are some steps Sitharaman may consider to spur foreign borrowing:

• She could raise the cap of 450 basis points above Libor, which limits overall foreign debt costs for Indian companies

• This could help lower-rated firms sell bonds abroad. Indian companies rated BBB currently borrow at more than 10%, about 3.8 percentage points more than their top-rated peers;

• Sitharaman could waive the withholding tax foreign investors need to pay on holdings of rupee-denominated debt sold by Indian companies abroad

• The waiver was offered between September 2018 to March 2019, but wasn’t extended as the highest global interest rates since the financial crisis deterred Indian borrowers. Since then, the three-month Libor has dropped by about 1 percentage point

• She could permit Indian property developers and housing finance lenders to sell overseas bonds for reasons beyond affordable housing projects

• New funding lines to the real estate sector, arguably ground zero of India’s economic slowdown, could help kickstart consumption and investment as the industry is the nation’s biggest job-creator.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
August 3,2020

The Drugs Controller General of India (DCGI) has given nod to the Serum Institute of India (SII) for conducting phase 2 and 3 human clinical trials of the Oxford University developed Covid-19 vaccine candidate in the country.

Government officials said that the approval for conducting phase 2 and 3 clinical trials by the SII was granted by DCGI Dr V G Somani late Sunday night after a thorough evaluation based on the recommendations of the Subject Expert Committee (SEC) on Covid-19.

"The firm has to submit safety data, evaluated by the Data Safety Monitoring Board (DSMB), to the CDSCO before proceeding to phase 3 clinical trials," a senior official said.

"As per the study design, each subject will be administered two doses four weeks apart (first dose on day one and second dose on day 29) following which the safety and immunogenicity will be assessed at predefined intervals," the official said.

As a rapid regulatory response, the expert panel at the Central Drugs Standard Control Organisation (CDSCO) on Friday, after a detailed deliberation and considering the data generated on the vaccine candidate in phase 1 and 2 of the Oxford University trial, had recommended granting permission for phase 2 and 3 clinical trials of the potential vaccine, 'Covishield', on healthy adults in India,  the officials said.

Currently, phase 2 and 3 clinical trials of the Oxford vaccine candidate is going on in the United Kingdom, phase 3 clinical trial in Brazil and phase 1 and 2 clinical trials in South Africa.

The officials said that the SII had submitted a revised proposal on Wednesday after the SEC on July 28, following deliberation over its application, had asked it to revise its protocol for the phase 2 and 3 clinical trials besides seeking some additional information.

The panel had also recommended that the clinical trial sites which have been proposed for the study be distributed across India.

According to the revised proposal by the SII, 1,600 people aged above 18 years will participate in the trials across 17 selected sites, including AIIMS-Delhi, B J Medical College in Pune, Rajendra Memorial Research Institute of Medical Sciences (RMRIMS) in Patna, Post Graduate Institute of Medical Education and Research in Chandigarh, AIIMS-Jodhpur, Nehru Hospital in Gorakhpur, Andhra Medical College in Visakhapatnam and JSS Academy of Higher Education and Research in Mysore.

"According to the application, it would conduct an observer-blind, randomised controlled study to determine the safety and immunogenicity of 'Covishield' on healthy Indian adults," the official said.

The SII, which has partnered with AstraZeneca, for manufacturing the Oxford vaccine candidate for Covid-19 had submitted its first application to the DCGI on July 25 seeking permission for conducting the phase 2 and 3 trials of the potential vaccine. 

Initial results of the first two-phases of trials of the vaccine conducted in five trial sites in the UK showed that it has an acceptable safety profile and homologous boosting increased antibody response, sources had said.

To introduce the vaccine, SII, the world's largest vaccine maker by number of doses produced and sold, has signed an agreement to manufacture the potential vaccine developed by the Jenner Institute (Oxford University) in collaboration with British-Swedish pharma company AstraZeneca. 

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.